# LACunar Intervention Trial 3

Submission date 29/10/2024	<b>Recruitment status</b> Recruiting	[X] Prospectively registered [_] Protocol
<b>Registration date</b> 24/12/2024	<b>Overall study status</b> Ongoing	<ul> <li>Statistical analysis plan</li> <li>Results</li> </ul>
Last Edited 28/01/2025	<b>Condition category</b> Nervous System Diseases	<ul><li>Individual participant data</li><li>[X] Record updated in last year</li></ul>

### Plain English summary of protocol

Background and study aims

Having a lacunar stroke increases the risk of another stroke, dementia, and loss of independence. A quarter of strokes, called lacunar strokes, are caused by disease of the smallest blood vessels in the brain. Lacunar strokes occur when small blood vessels deep within the brain become damaged and do not supply oxygen and nutrients well. The blood supply to part of the brain is interrupted. When there is an interruption in blood supply to part of the brain, the lacunar stroke happens.

It affects about 35000 people per year in the UK. This 'small vessel disease' can also cause problems with thinking, balance and walking and can sometimes lead to dementia. There are no treatments yet to help the small blood vessels work better. As a result, damage to the brain may continue to build up.

We have found two drugs that may reduce damage to the small blood vessels in the brain and, therefore, could prevent strokes and thinking problems caused by small vessel disease. One drug, called cilostazol, is most used in the UK to treat problems with the blood supply to the legs but is used to prevent more strokes from happening in many other countries.

The other drug, called isosorbide mononitrate, is commonly used worldwide, including in the UK, to treat angina (chest pains caused by poor blood supply to the heart).

A network of 60 UK hospitals will identify patients after lacunar stroke and invite them to participate. LACI-3 will need 1300 participants to confirm whether isosorbide mononitrate and cilostazol, taken alone or together, reduce the risk of another stroke, dementia, and loss of independence. Participants will take study tablets for 18 months, during which we will collect information on health, cognition, and quality of life.

Who can participate?

Adults aged 30 years and older who have had a lacunar stroke.

What does the study involve?

Participants will be randomly assigned to one of the four groups:

- 1. They may be given cilostazol only.
- 2. They may be given isosorbide mononitrate only.
- 3. Both cilostazol and isosorbide mononitrate will be given.
- 4. Neither cilostazol nor isosorbide mononitrate is given.

Everyone gets guideline standard medical care.

Participants will be taking part in LACI-3 for 18 months and follow up five times during their treatment by phone and post.

What are the possible benefits and risks of participating?

The findings of LACI-3 will be used in everyday clinical practice in the NHS to care for people with lacunar stroke and prevent future stroke and dementia before symptoms develop.

The trial has been designed to minimise the participants' burden, and the trial materials allow them to contact the trial hospital, central office, or an independent advisor at any time should they need advice. The potential side effects of the study drugs are well-known, and the hospital research team will explain the risks to the participants. Based on the results from the LACI1/2 trials, the study drugs were well-tolerated and safe.

The follow-up will be delivered remotely by phone and post at regular intervals, and participants will be asked about any new drug symptoms or health problems. To minimise travel to the hospital site, they will receive a re-supply of the study drug(s) by post or courier. Participants may find completing the follow-up questionnaires inconvenient; however, the research teams will use each follow-up visit to monitor participants' health, including blood pressure checks. Participants will also be informed that they can ask someone to complete the follow-ups on their behalf if they have difficulties in writing or visual impairment. Participants will have a chance to complete a postal questionnaire by phone if preferred.

Where is the study run from? University of Edinburgh (UK)

When is the study starting and how long is it expected to run for? October 2024 to December 2028

Who is funding the study? National Institute for Health and Care Research (NIHR) Health Technology Assessment (UK)

Who is the main contact? laci-3@ed.ac.uk

## **Contact information**

**Type(s)** Scientific, Principal Investigator

**Contact name** Prof Joanna Wardlaw

**ORCID ID** http://orcid.org/0000-0002-9812-6642

**Contact details** Centre for Clinical Brain Sciences First floor Chancellor's Building 49 Little France Crescent Edinburgh United Kingdom EH16 4SB

Joanna.Wardlaw@ed.ac.uk

**Type(s)** Public

**Contact name** Ms Kasia Adamczuk

ORCID ID http://orcid.org/0009-0009-5158-6818

**Contact details** Centre for Clinical Brain Sciences (CCBS) University of Edinburgh Chancellor's Building Room 49 Little France Crescent Edinburgh United Kingdom EH16 4SB

laci-3@ed.ac.uk

## Additional identifiers

**EudraCT/CTIS number** Nil known

**IRAS number** 1008629

**ClinicalTrials.gov number** Nil known

Secondary identifying numbers AC24127

## Study information

### Scientific Title

The LACunar Intervention Trial 3 (LACI-3). Assessment of efficacy and safety of cilostazol and isosorbide mononitrate to prevent adverse outcomes in patients with cerebral small vessel disease (lacunar) ischaemic stroke.

#### Acronym LACI-3

**Study objectives** 

Primary research question:

For adults surviving lacunar ischaemic stroke, does a policy of starting a drug called cilostazol or a drug called isosorbide mononitrate or starting both of those drugs result in a reduction of problems with memory and thinking compared to continuing routine stroke prevention therapy only?

The secondary objectives of the LACI-3 study are to determine if two tested drugs called cilostazol and isosorbide mononitrate, taken alone or together:

1. Reduces dependency

2. Helps prevent small vessel disease (problems in tiny blood vessels deep in the brain) from causing another stroke, heart attack or death

- 3. Improves mood
- 4. Improves quality of life
- 5. Reduces use of NHS or social care services
- 6. If they can be used safely in patients with a lacunar stroke
- 7. And if patients can take them over several years

#### Ethics approval required

Ethics approval required

#### Ethics approval(s)

Approved 20/01/2025, Scotland B Research Ethics Committee (Waverley Gate, 2 - 4 Waterloo Place , Edinburgh, EH1 3EG, United Kingdom; +44 7814609032; Manx.Neill@nhslothian.scot.nhs. uk), ref: 24/SS/0095

#### Study design

Prospective randomized open-label blinded endpoint factorial trial

#### Primary study design

Interventional

**Secondary study design** Randomised controlled trial

Study setting(s) Hospital

**Study type(s)** Safety, Efficacy

#### Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

#### Health condition(s) or problem(s) studied

Lacunar (small vessel) ischaemic stroke

#### Interventions

The intervention involves random allocation to one of the four treatment groups, in addition to the guideline standard care after lacunar ischaemic stroke, using an electronic randomisation system:

- 1. Isosorbide mononitrate (ISMN) oral:
- 1.1. Slow release 50 mg once daily or
- 1.2. Non-slow-release 20 or 25 mg twice daily
- 2. Cilostazol 100 mg oral twice daily
- 3. Both ISMN and cilostazol same doses as above
- 4. Neither ISMN nor cilostazol

A target dose of isosorbide mononitrate is 40-60 mg daily. If a slow-release ISMN is not available, the non-slow-release tablets may be used.

The IMP is defined by the active substance only, therefore all authorised brands may be used. There is no placebo. The comparator will be a standard care alone including guideline stroke secondary prevention prescribed post-stroke as per national guidelines.

The trial treatment period is 18 months.

There are five follow-up timepoints after randomisation:

- 1. 1–2-week follow-up by phone
- 2. 3–4-week follow-up by phone
- 3. 6-month follow-up by post and phone
- 4. 12-month follow-up by post and phone
- 5. 18-month follow-up by post and phone

#### Intervention Type

Drug

#### Pharmaceutical study type(s)

Prophylaxis, Therapy, Safety, Others (Tolerability and cost effectiveness)

#### Phase

Phase III

#### Drug/device/biological/vaccine name(s)

Cilostazol, isosorbide mononitrate

#### Primary outcome measure

Cognitive impairment after lacunar ischaemic stroke will be evaluated at 18 months after randomisation using the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) scale operationalised, a 7-level ordinal cognitive impairment scale using subscores of the Telephone Montreal Cognitive Assessment (tMOCA), Telephone Interview for Cognitive Status (TICS), animal naming, clinical dementia diagnosis measured at 6, 12 and 18 months.

#### Secondary outcome measures

Secondary outcome measures:

The secondary outcomes will be evaluated at 18 months after randomisation:

1. Dependency (defined as mRS>2) is measured using a Modified Rankin Score at 6, 12 and 18 months

2. Cognitive impairment or dementia are measured at 6, 12 and 18 months using:

- 2.1. Telephone-Montreal Cognitive Assessment (t-MOCA)
- 2.2. Telephone Interview for Cognitive Status (TICS)
- 2.3. Concentration (from Mini-Mental State Examination [MMSE])

2.4. Animal naming

3. Clinical outcomes are measured using postal/telephone questionnaires and medical notes during 18 months after randomisation:

3.1. Recurrent ischaemic stroke or transient ischaemic Attack (TIA) or haemorrhagic stroke

3.2. Fatal or non-fatal myocardial infarction (MI)

3.3. Death, due to vascular and any cause

4. Safety outcomes are measured using reported Serious Adverse Events (SAEs) during 18 months after randomisation

5. IMP symptoms are measured using telephone/postal questionnaires at 1-2 weeks, 3-4 weeks, and 6, 12 and 18 months

6. Quality of life is measured using:

6.1. Stroke Impact Scale (individual domains and global) postal questionnaire at 6, 12 and 18 months

6.2. EQ5D-5L, EQ-VAS of the EuroQol paper questionnaire at randomisation and 18 months

6.3. Mood is measured using the ZUNG depression rating scale at 6, 12 and 18 months

6.4. Composite of recurrent stroke or TIA, MI, death, dependency (mRS>2), cognitive impairment at 18 months after randomisation

6.5. Global Clinical Outcome of recurrent stroke or TIA, MI, death, mRS>2, cognitive impairment, QoL, mood (ZUNG) at 18 months after randomisation

6.6. Health economic usage using a postal questionnaire is measured 18 months after randomisation

Tertiary outcome measures:

Blood pressure measures will be evaluated at 18 months after randomisation using blood pressure measurements made by participants or available from GP or hospital medical records as a part of the routine stroke prevention therapy at randomisation, 1-2 weeks, 3-4 weeks and at 6, 12 and 18 months.

### Overall study start date

24/10/2024

### **Completion date**

31/12/2028

## Eligibility

### Key inclusion criteria

#### 1. Age ≥30 years

2. Clinical stroke syndrome compatible with a lacunar stroke and brain imaging (MRI preferred but CT allowed) at the time of the stroke shows a relevant recent small subcortical infarct, or if no relevant infarct then no other explanation for symptoms is seen

3. Genetic forms of SVD (e.g. CADASIL) may be included if they present with a lacunar stroke 4. Capacity to give consent in the opinion of the PI or any delegated member of the research team

### Participant type(s)

Patient

#### **Age group** Adult

Lower age limit

30 Years

**Sex** Both

Target number of participants

1300

### Key exclusion criteria

General Exclusion Criteria:

1. Less than 24 hours since onset of the lacunar stroke or patient on dual antiplatelet drugs

2. Stroke mechanism with definite treatment indication (e.g. cardioembolism, ipsilateral carotid stenosis)

3. Other explanation for the lacunar stroke symptoms (i.e., recent cortical infarct, haemorrhage or tumour)

4. Other active neurological disease (e.g., brain tumour, multiple sclerosis, recurrent seizures, neurodevelopmental disorder - well-controlled epilepsy present prior to the lacunar stroke, a single seizure at onset of the stroke, or provoked seizure, is not an exclusion)

5. Contraindication to both trial drugs in section 4.3 of the SPCs (patients with a contraindication to one trial drug may still be randomised to the other trial drug)

6. Indication for either trial drug (patient already prescribed one trial drug may still be randomised to the other trial drug)

7. Dependent (mRS>2)

8. Clinical diagnosis of dementia

9. Planned surgery during the trial period including carotid endarterectomy. Note prior and apparently successful carotid endarterectomy (or other surgery) is not an exclusion criterion and patients who would otherwise be eligible but require endarterectomy first may be randomised after recovery from successful endarterectomy

10. Unable to swallow

11. Diagnosis of hypotension, defined as sitting systolic blood pressure less than 100mmHg

- 12. History of drug overdose or attempted suicide
- 13. Unlikely to be available for follow-up at 18 months

14. Unlikely to comply with study procedures and follow-up procedures for whatever reason (e.

g., history of poor medication compliance) in the opinion of the randomising physician

15. Pregnant, breast-feeding, or of child-bearing potential and not using highly effective contraception

16. Renal impairment (creatinine clearance <25 ml/min)

17. Hepatic impairment

18. Currently prescribed dual antiplatelet treatment (single antiplatelet is not an exclusion); patients can be randomised into the trial once the 28-day period of dual antiplatelet for guideline secondary prevention following the acute lacunar ischaemic stroke has completed 19. Previously enrolled in LACI-3

20. Enrolled in a study that precludes co-enrolment with LACI-3

Cilostazol Exclusion Criteria (still allows randomisation to ISMN):

1. Definite indication for (i.e., already prescribed) Cilostazol, or definite contraindication to Cilostazol as per SPCs section 6.1.8.

2. Prohibited medications to Cilostazol (see sections 4.5 of the appended SPCs and protocol section 6.7.3)

3. Active cardiac disease (atrial fibrillation, myocardial infarction in past 6 months, active angina,

symptomatic cardiac failure)

4. Bleeding tendency (e.g., known platelets <100, active peptic ulcer, history of intracranial haemorrhage such as subdural haematoma, subarachnoid haemorrhage, intracerebral haemorrhage, but not asymptomatic haemorrhagic transformation of infarction or a few microbleeds, taking anticoagulant medication)

ISMN Exclusion Criteria (still allows randomisation to Cilostazol):

1. Definite indication for (i.e., already prescribed) ISMN, or definite contraindication to ISMN as per SPCs

2. Prohibited medications to ISMN (see sections 4.5 of the appended SPCs and protocol section 6.7.3)

Date of first enrolment 03/03/2025

Date of final enrolment 30/06/2027

## Locations

**Countries of recruitment** England

Northern Ireland

Scotland

United Kingdom

Wales

**Study participating centre Royal Infirmary of Edinburgh** Centre for Clinical Brain Sciences Chancellor's Building 49 Little France Crescent Lothian United Kingdom EH16 4SB

## Sponsor information

**Organisation** University of Edinburgh

**Sponsor details** 

Clinical Research Governance Usher Building BioQuarter 57 Little France Road Edinburgh Scotland United Kingdom EH16 4UX +44 (0)131 242 936 Fiach.O'Mahony@ed.ac.uk

Sponsor type

University/education

Website

https://www.accord.scot/

ROR https://ror.org/01nrxwf90

**Organisation** NHS Lothian

Sponsor details 57 Little France Road Edinburgh BioQuarter Gate 3 Edinburgh Scotland United Kingdom EH16 4UX +44 (0)131 2423359 Heather.Charles@nhslothian.scot.nhs.uk

**Sponsor type** Hospital/treatment centre

Website https://www.accord.scot/

ROR https://ror.org/03q82t418

## Funder(s)

**Funder type** Government **Funder Name** Health Technology Assessment Programme

Alternative Name(s) NIHR Health Technology Assessment Programme, HTA

**Funding Body Type** Government organisation

Funding Body Subtype National government

**Location** United Kingdom

## **Results and Publications**

### Publication and dissemination plan

- 1. Peer-reviewed scientific journals
- 2. Conference presentation
- 3. Publication on website
- 4. Other publication

#### Intention to publish date

31/12/2029

#### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from Professor Joanna Wardlaw (Joanna.Wardlaw@ed.ac.uk). Researchers may apply to use a de-identified version of the dataset for prospective individual patient data meta-analysis and a data dictionary after 1 year of the publication of the results. A LACI-3 data-sharing committee will assess the written proposals and decide whether data use is appropriate. A datasharing agreement must be in place before any data sharing.

#### IPD sharing plan summary

Available on request